Necroptosis in niemann–pick disease, type C1: A potential therapeutic target

Cell Death and Disease

Volumn 7, Issue 3, 2016, Pages

  Cougnoux, A ^a   Cluzeau, C ^a   Mitra, S ^b   Li, R ^c   Williams, I ^a   Burkert, K ^a   Xu, X ^c   Wassif, C A ^a   Zheng, W ^c   Porter, F D ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN KINASE 1; RECEPTOR INTERACTING PROTEIN KINASE 3; UNCLASSIFIED DRUG; AGFG1 PROTEIN, HUMAN; CARRIER PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MEMBRANE PROTEIN; NPC1 PROTEIN, HUMAN; NPC1 PROTEIN, MOUSE; NUCLEOPORIN; PROTEIN; RALBP1 PROTEIN, MOUSE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, HUMAN; RIPK3 PROTEIN, MOUSE; RNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLAR TISSUE; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NECROPTOSIS; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURKINJE CELL; ANIMAL; CELL LINE; GENETICS; METABOLISM; MUTANT MOUSE STRAIN; NECROSIS; NEURAL STEM CELL; NIEMANN-PICK DISEASE, TYPE C; PATHOLOGY;

ANIMALS; CARRIER PROTEINS; CELL LINE; GTPASE-ACTIVATING PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, MUTANT STRAINS; NECROSIS; NEURAL STEM CELLS; NIEMANN-PICK DISEASE, TYPE C; NUCLEAR PORE COMPLEX PROTEINS; PROTEINS; PURKINJE CELLS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RNA-BINDING PROTEINS;

EID: 85017320460     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.16     Document Type: Article

References (51)

1. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis 2010; 5: 16.
2. Wassif CA, Cross JL, Iben J, Sanchez-Pulido L, Cougnoux A, Platt FM et al. High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet Med 2015; 18: 41–48.
3. Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta 2004; 1685: 48–62.
4. Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliot-Smith E, Sillence DJ et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 2008; 14: 1247–1255.
5. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007; 6: 765–772.
6. Wraith JE, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 2010; 99: 351–357.
7. Sarkar S, Carroll B, Buganim Y, Maetzel D, Ng AH, Cassady JP et al. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease. Cell Rep 2013; 5: 1302–1315.
8. Maetzel D, Sarkar S, Wang H, Abi-Mosleh L, Xu P, Cheng AW et al. Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells. Stem Cell Rep 2014; 2: 866–880.
9. Elrick MJ, Yu T, Chung C, Lieberman AP. Impaired proteolysis underlies autophagic dysfunction in Niemann-Pick type C disease. Hum Mol Genet 2012; 21: 4876–4887.
10. Wu YP, Mizukami H, Matsuda J, Saito Y, Proia RL, Suzuki K. Apoptosis accompanied by upregulation of TNF-alpha death pathway genes in the brain of Niemann-Pick type C disease. Mol Genet Metab 2005; 84: 9–17.
11. Erickson RP, Bernard O. Studies on neuronal death in the mouse model of Niemann-Pick C disease. J Neurosci Res 2002; 68: 738–744.
12. Hunter CL, Quintero EM, Gilstrap L, Bhat NR, Granholm AC. Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning. Eur J Neurosci 2004; 19: 3305–3316.
13. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107–120.
14. Galluzzi L, Vanden Berghe T, Vanlangenakker N, Buettner S, Eisenberg T, Vandenabeele P et al. Programmed necrosis from molecules to health and disease. Int Rev Cell Mol Biol 2011; 289: 1–35.
15. Weinglass AB, Kohler MG, Nketiah EO, Liu J, Schmalhofer W, Thomas A et al. Madin-Darby canine kidney II cells: a pharmacologically validated system for NPC1L1-mediated cholesterol uptake. Mol Pharmacol 2008; 73: 1072–1084.
16. Quintero EM, Willis LM, Zaman V, Lee J, Boger HA, Tomac A et al. Glial cell line-derived neurotrophic factor is essential for neuronal survival in the locus coeruleus-hippocampal noradrenergic pathway. Neuroscience 2004; 124: 137–146.
17. Patel SC, Suresh S, Kumar U, Hu CY, Cooney A, Blanchette-Mackie EJ et al. Localization of Niemann-Pick C1 protein in astrocytes: implications for neuronal degeneration in Niemann-Pick type C disease. Proc Natl Acad Sci USA 1999; 96: 1657–1662.
18. German DC, Quintero EM, Liang CL, Ng B, Punia S, Xie C et al. Selective neurodegeneration, without neurofibrillary tangles, in a mouse model of Niemann-Pick C disease. J Comp Neurol 2001; 433: 415–425.
19. Hung YH, Faux NG, Killilea DW, Yanjanin N, Firnkes S, Volitakis I et al. Altered transition metal homeostasis in Niemann-Pick disease, type C1. Metallomics 2014; 6: 542–553.
20. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313–321.
21. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 2010; 22: 263–268.
22. Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD et al. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med 2014; 20: 204–208.
23. Zhu S, Zhang Y, Bai G, Li H. Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease. Cell Death Dis 2011; 2: e115.
24. Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 2014; 81: 1001–1008.
25. Wehrmann ZT, Hulett TW, Huegel KL, Vaughan KT, Wiest O, Helquist P et al. Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts. PLoS One 2012; 7: e48561.
26. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112–119.
27. Yanjanin NM, Velez JI, Gropman A, King K, Bianconi SE, Conley SK et al. Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 132–140.
28. Higashi Y, Murayama S, Pentchev PG, Suzuki K. Cerebellar degeneration in the Niemann-Pick type C mouse. Acta Neuropathol 1993; 85: 175–184.
29. te Vruchte D, Lloyd-Evans E, Veldman RJ, Neville DC, Dwek RA, Platt FM et al. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. J Biol Chem 2004; 279: 26167–26175.
30. Cologna SM, Cluzeau CV, Yanjanin NM, Blank PS, Dail MK, Siebel S et al. Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1. J Inherit Metab Dis 2014; 37: 83–92.
31. Kennedy BE, Madreiter CT, Vishnu N, Malli R, Graier WF, Karten B. Adaptations of energy metabolism associated with increased levels of mitochondrial cholesterol in Niemann-Pick type C1-deficient cells. J Biol Chem 2014; 289: 16278–16289.
32. Ohara S, Ukita Y, Ninomiya H, Ohno K. Axonal dystrophy of dorsal root ganglion sensory neurons in a mouse model of Niemann-Pick disease type C. Exp Neurol 2004; 187: 289–298.
33. Fu R, Wassif CA, Yanjanin NM, Watkins-Chow DE, Baxter LL, Incao A et al. Efficacy of N-acetylcysteine in phenotypic suppression of mouse models of Niemann-Pick disease, type C1. Hum Mol Genet 2013; 22: 3508–3523.
34. Williams IM, Wallom KL, Smith DA, Al Eisa N, Smith C, Platt FM. Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice. Neurobiol Dis 2014; 67: 9–17.
35. Peake KB, Hayashi H, Campenot R, Vance D, Vance J. Inflammation in the Niemann-Pick type-C brain. FASEB J 2007; 21: 1.
36. Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy JM. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1 − / − mouse. Proc Natl Acad Sci 2009; 106: 2377–2382.
37. Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 2001; 11: 1283–1287.
38. Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy JM. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/-mouse. Proc Natl Acad Sci USA 2009; 106: 2377–2382.
39. Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 2009; 4: e6951.
40. Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ 2013; 20: 366.
41. Zheng W, Degterev A, Hsu E, Yuan J, Yuan C. Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorg Med Chem Lett 2008; 18: 4932–4935.
42. Wu Z, Li Y, Cai Y, Yuan J, Yuan C. A novel necroptosis inhibitor-necrostatin-21 and its SAR study. Bioorg Med Chem Lett 2013; 23: 4903–4906.
43. Wang K, Li J, Degterev A, Hsu E, Yuan J, Yuan C. Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5. Bioorg Med Chem Lett 2007; 17: 1455–1465.
44. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.
45. McGaha TL, Huang L, Lemos H, Metz R, Mautino M, Prendergast GC et al. Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev 2012; 249: 135–157.
46. Suzuki M, Sugimoto Y, Ohsaki Y, Ueno M, Kato S, Kitamura Y et al. Endosomal accumulation of Toll-like receptor 4 causes constitutive secretion of cytokines and activation of signal transducers and activators of transcription in Niemann–Pick disease type C (NPC) fibroblasts: a potential basis for glial cell activation in the NPC brain. J Neurosci 2007; 27: 1879–1891.
47. You Z, Savitz SI, Yang J, Degterev A, Yuan J, Cuny GD et al. Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab 2008; 28: 1564–1573.
48. Xu X, Chua KW, Chua CC, Liu CF, Hamdy RC, Chua BH. Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury. Brain Res 2010; 1355: 189–194.
49. Yu D, Swaroop M, Wang M, Baxa U, Yang R, Yan Y et al. Niemann-Pick disease type C: induced pluripotent stem cell-derived neuronal cells for modeling neural disease and evaluating drug efficacy. J Biomol Screen 2014; 19: 1164–1173.
50. Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, Brown A et al. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 1997; 277: 232–235.
51. Cluzeau CV, Watkins-Chow DE, Fu R, Borate B, Yanjanin N, Dail MK et al. Microarray expression analysis and identification of serum biomarkers for Niemann-Pick disease, type C1. Hum Mol Genet 2012; 21: 3632–3646.